000180148 001__ 180148
000180148 005__ 20240229145608.0
000180148 0247_ $$2doi$$a10.1007/s10143-022-01815-2
000180148 0247_ $$2pmid$$apmid:35633420
000180148 0247_ $$2ISSN$$a0344-5607
000180148 0247_ $$2ISSN$$a1437-2320
000180148 037__ $$aDKFZ-2022-01135
000180148 041__ $$aEnglish
000180148 082__ $$a610
000180148 1001_ $$aKong, Lu$$b0
000180148 245__ $$aFive-year symptomatic hemorrhage risk of untreated brainstem cavernous malformations in a prospective cohort.
000180148 260__ $$aNew York$$bSpringer$$c2022
000180148 3367_ $$2DRIVER$$aarticle
000180148 3367_ $$2DataCite$$aOutput Types/Journal article
000180148 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1662121851_13424
000180148 3367_ $$2BibTeX$$aARTICLE
000180148 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180148 3367_ $$00$$2EndNote$$aJournal Article
000180148 500__ $$a2022 Aug;45(4):2961-2973
000180148 520__ $$aHemorrhage of brainstem cavernous malformation (CM) would cause various symptoms and severe disability. The study aimed to elaborate on the 5-year actuarial cumulative hazard of symptomatic hemorrhage. Patients diagnosed in our institute between 2009 and 2013 were prospectively registered. All clinical data were obtained, follow-up was performed, and risk factors were evaluated. Four hundred sixty-eight patients (217 female, 46.4%) were included in the study with a median follow-up duration of 79.0 months. A total of 137 prospective hemorrhages occurred in 107 patients (22.9%) during 1854.0 patient-years. Multivariate Cox analysis found age ≥ 55 years (hazard ratio (HR) 2.166, p = 0.002), DVA (HR 1.576, p = 0.026), superficial-seated location (HR 1.530, p = 0.047), and hemorrhage on admission (HR 2.419, p = 0.026) as independent risk factors for hemorrhage. The 5-year cumulative hazard of hemorrhage was 30.8% for the overall cohort, 47.8% for 60 patients with age ≥ 55 years, 43.7% for 146 patients with DVA, 37.9% for 272 patients with superficial-seated lesions, and 37.2% for 341 patients with hemorrhage on admission. As a stratified analysis, within subcohort of 341 patients with a hemorrhagic presentation, age ≥ 55 years (HR 3.005, p < 0.001), DVA (HR 1.801, p = 0.010), and superficial-seated location (HR 2.276, p = 0.001) remained independently significant. The 5-year cumulative hazard of hemorrhage was 52.0% for 119 patients with both DVA and hemorrhagic presentation. The 5-year cumulative hemorrhagic risk was 30.8% and was higher in subgroups if harboring risk factors that helped to predict potential hemorrhagic candidates and were useful for treatment decision-making.Clinical Trial Registration-URL: http://www.chictr.org.cn Unique identifier: ChiCTR-POC-17011575.
000180148 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000180148 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180148 650_7 $$2Other$$aBrainstem cavernous malformation
000180148 650_7 $$2Other$$aCavernoma
000180148 650_7 $$2Other$$aCerebral cavernous malformation
000180148 650_7 $$2Other$$aHemorrhage risk
000180148 650_7 $$2Other$$aNatural history
000180148 7001_ $$0P:(DE-He78)88de8ba75b18dd92d742eb7eab04a1b3$$aMa, Xiu-Jian$$b1$$udkfz
000180148 7001_ $$aXu, Xiao-Ying$$b2
000180148 7001_ $$aLiu, Pan-Pan$$b3
000180148 7001_ $$aWu, Ze-Yu$$b4
000180148 7001_ $$aZhang, Li-Wei$$b5
000180148 7001_ $$aZhang, Jun-Ting$$b6
000180148 7001_ $$aWu, Zhen$$b7
000180148 7001_ $$aWang, Liang$$b8
000180148 7001_ $$00000-0003-0629-0742$$aLi, Da$$b9
000180148 773__ $$0PERI:(DE-600)1474861-7$$a10.1007/s10143-022-01815-2$$n4$$p2961-2973$$tNeurosurgical review$$v45$$x0344-5607$$y2022
000180148 909CO $$ooai:inrepo02.dkfz.de:180148$$pVDB
000180148 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)88de8ba75b18dd92d742eb7eab04a1b3$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000180148 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000180148 9141_ $$y2022
000180148 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-26$$wger
000180148 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000180148 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000180148 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000180148 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000180148 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000180148 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000180148 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROSURG REV : 2021$$d2022-11-08
000180148 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-08
000180148 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-08
000180148 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-08
000180148 9201_ $$0I:(DE-He78)A240-20160331$$kA240$$lA240 Molekulare Neurogenetik$$x0
000180148 980__ $$ajournal
000180148 980__ $$aVDB
000180148 980__ $$aI:(DE-He78)A240-20160331
000180148 980__ $$aUNRESTRICTED